PRECISION BIOSCIENCES INC (DTIL)
Data as of , from SEC Form 4 filings.
See up to 3 months of DTIL. The 7-day demo opens the 1M and 3M ranges and puts DTIL on your watchlist.
Start 7-day demoLatest DTIL insider trades
Stanley Frankel - DirectorOpen-market purchase$6K
Melinda Brown - DirectorOpen-market purchase$7K- Geno J. Germano - DirectorOpen-market purchase$16K
- Michael Amoroso - OfficerOpen-market sale$79K
- John Alexander Kelly - OfficerOpen-market sale$31K
- Dario Scimeca - OfficerOpen-market sale$19K
- J. Jefferson Smith - OfficerOpen-market sale$19K
- Michael Amoroso - OfficerOpen-market sale$145K
About PRECISION BIOSCIENCES INC (DTIL)
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- DURHAM, NC
- 67
- 2019
- XNAS
https://www.precisionbiosciences.comSEC filings for DTIL on EDGAR
DTIL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 4,744 | $30K |
DTIL insider transactions (Form 4)
7338 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Stanley Frankel - Director | Open-market purchase | Common Stock | 1,000 | $6.00 | $6K | |
| Melinda Brown - Director | Open-market purchase | Common Stock | 1,135 | $6.27 | $7K | |
| Geno J. Germano - Director | Open-market purchase | Common Stock | 2,609 | $6.28 | $16K | |
| Melinda Brown - Director | Grant or award | Restricted Stock Units | 20,979 | $0.00 | - | |
| Stanley Frankel - Director | Grant or award | Restricted Stock Units | 20,979 | $0.00 | - | |
| Geno J. Germano - Director | Grant or award | Restricted Stock Units | 20,979 | $0.00 | - | |
| Shari Lisa Pire - Director | Grant or award | Restricted Stock Units | 20,979 | $0.00 | - | |
| Kevin Buehler - Director | Grant or award | Restricted Stock Units | 20,979 | $0.00 | - | |
| J. Jefferson Smith - Officer | Grant or award | Restricted Stock Units | 57,389 | $0.00 | - | |
| Dario Scimeca - Officer | Grant or award | Restricted Stock Units | 107,604 | $0.00 | - | |
| John Alexander Kelly - Officer | Grant or award | Restricted Stock Units | 193,688 | $0.00 | - | |
| Michael Amoroso - Officer | Grant or award | Restricted Stock Units | 573,888 | $0.00 | - | |
| Kevin Buehler - Director | Option exercise | Common Stock | 21,000 footnote F1 | - footnote F2 | - | |
| Kevin Buehler - Director | Option exercise | Restricted Stock Units | 21,000 | $0.00 | - | |
| ||||||
| Stanley Frankel - Director | Option exercise | Common Stock | 21,000 footnote F1 | - footnote F2 | - | |
| Stanley Frankel - Director | Option exercise | Restricted Stock Units | 21,000 | $0.00 | - | |
| ||||||
| Melinda Brown - Director | Option exercise | Common Stock | 21,000 footnote F1 | - footnote F2 | - | |
| Melinda Brown - Director | Option exercise | Restricted Stock Units | 21,000 | $0.00 | - | |
| ||||||
| Shari Lisa Pire - Director | Option exercise | Common Stock | 21,000 footnote F1 | - footnote F2 | - | |
| Shari Lisa Pire - Director | Option exercise | Restricted Stock Units | 21,000 | $0.00 | - | |
| ||||||
| Geno J. Germano - Director | Option exercise | Common Stock | 21,000 footnote F1 | - footnote F2 | - | |
| Geno J. Germano - Director | Option exercise | Restricted Stock Units | 21,000 | $0.00 | - | |
| ||||||
| Michael Amoroso - Officer | Option exercise | Common Stock | 67,797 footnote F1 | $0.00 footnote F2 | - | |
| Michael Amoroso - Officer | Open-market sale | Common Stock | 20,559 | $3.84 | $79K | |
| Michael Amoroso - Officer | Option exercise | Restricted Stock Units | 67,797 | $0.00 | - | |
| ||||||
| John Alexander Kelly - Officer | Option exercise | Common Stock | 27,584 footnote F1 | $0.00 footnote F2 | - | |
| John Alexander Kelly - Officer | Open-market sale | Common Stock | 8,149 | $3.84 | $31K | |
| John Alexander Kelly - Officer | Option exercise | Restricted Stock Units | 27,584 | $0.00 | - | |
| ||||||
| Dario Scimeca - Officer | Option exercise | Common Stock | 16,667 footnote F1 | $0.00 footnote F2 | - | |
| Dario Scimeca - Officer | Open-market sale | Common Stock | 4,925 | $3.84 | $19K | |
| Dario Scimeca - Officer | Option exercise | Restricted Stock Units | 16,667 | $0.00 | - | |
| ||||||
| J. Jefferson Smith - Officer | Option exercise | Common Stock | 16,667 footnote F1 | $0.00 footnote F2 | - | |
| J. Jefferson Smith - Officer | Open-market sale | Common Stock | 4,925 | $3.84 | $19K | |
| J. Jefferson Smith - Officer | Option exercise | Restricted Stock Units | 16,667 | $0.00 | - | |
| ||||||
| Michael Amoroso - Officer | Option exercise | Common Stock | 8,888 footnote F1 | - footnote F2 | - | |
| Michael Amoroso - Officer | Option exercise | Common Stock | 37,069 footnote F1 | - footnote F2 | - | |
| Michael Amoroso - Officer | Option exercise | Common Stock | 69,421 footnote F1 | - footnote F2 | - | |
| Michael Amoroso - Officer | Open-market sale | Common Stock | 34,799 | $4.17 footnote F4 | $145K | |
| Michael Amoroso - Officer | Option exercise | Restricted Stock Units | 8,888 | $0.00 | - | |
| Michael Amoroso - Officer | Option exercise | Restricted Stock Units | 37,069 | $0.00 | - | |
| Michael Amoroso - Officer | Option exercise | Restricted Stock Units | 69,421 | $0.00 | - | |
| ||||||
| Dario Scimeca - Officer | Option exercise | Common Stock | 1,978 footnote F1 | $0.00 footnote F2 | - | |
| Dario Scimeca - Officer | Option exercise | Common Stock | 8,425 footnote F1 | $0.00 footnote F2 | - | |
| Dario Scimeca - Officer | Option exercise | Common Stock | 14,908 footnote F1 | $0.00 footnote F2 | - | |
| Dario Scimeca - Officer | Open-market sale | Common Stock | 8,854 | $4.03 | $36K | |
| Dario Scimeca - Officer | Option exercise | Restricted Stock Units | 1,978 | $0.00 | - | |
| Dario Scimeca - Officer | Option exercise | Restricted Stock Units | 8,425 | $0.00 | - | |
| Dario Scimeca - Officer | Option exercise | Restricted Stock Units | 14,908 | $0.00 | - | |
| ||||||
| John Alexander Kelly - Officer | Option exercise | Common Stock | 3,888 footnote F1 | - footnote F2 | - | |
| John Alexander Kelly - Officer | Option exercise | Common Stock | 13,900 footnote F1 | - footnote F2 | - | |
| John Alexander Kelly - Officer | Option exercise | Common Stock | 26,575 footnote F1 | - footnote F2 | - | |
| John Alexander Kelly - Officer | Open-market sale | Common Stock | 15,213 | $4.03 | $61K | |
| John Alexander Kelly - Officer | Option exercise | Restricted Stock Units | 3,888 | $0.00 | - | |
| John Alexander Kelly - Officer | Option exercise | Restricted Stock Units | 13,900 | $0.00 | - | |
| John Alexander Kelly - Officer | Option exercise | Restricted Stock Units | 26,575 | $0.00 | - | |
| ||||||
| J. Jefferson Smith - Officer | Option exercise | Common Stock | 2,500 footnote F1 | - footnote F2 | - | |
| J. Jefferson Smith - Officer | Option exercise | Common Stock | 10,447 footnote F1 | - footnote F2 | - | |
| J. Jefferson Smith - Officer | Option exercise | Common Stock | 16,219 footnote F1 | - footnote F2 | - | |
| J. Jefferson Smith - Officer | Open-market sale | Common Stock | 10,200 | $4.03 | $41K | |
| J. Jefferson Smith - Officer | Option exercise | Restricted Stock Units | 2,500 | $0.00 | - | |
| J. Jefferson Smith - Officer | Option exercise | Restricted Stock Units | 10,447 | $0.00 | - | |
| J. Jefferson Smith - Officer | Option exercise | Restricted Stock Units | 16,219 | $0.00 | - | |
| ||||||
| John Alexander Kelly - Officer | Option exercise | Restricted Stock Units | 3,605 | $0.00 | - | |
| John Alexander Kelly - Officer | Option exercise | Common Stock | 3,605 footnote F1 | $0.00 footnote F2 | - | |
| John Alexander Kelly - Officer | Open-market sale | Common Stock | 1,303 | $6.49 | $8K | |
| ||||||
| Dario Scimeca - Officer | Option exercise | Restricted Stock Units | 1,835 | $0.00 | - | |
| Dario Scimeca - Officer | Option exercise | Common Stock | 1,835 footnote F1 | $0.00 footnote F2 | - | |
| Dario Scimeca - Officer | Open-market sale | Common Stock | 665 | $6.49 | $4K | |
| ||||||
| Michael Amoroso - Officer | Option exercise | Common Stock | 9,444 footnote F1 | $0.00 footnote F2 | - | |
| Michael Amoroso - Officer | Open-market sale | Common Stock | 3,409 | $6.49 | $22K | |
| Michael Amoroso - Officer | Option exercise | Restricted Stock Units | 9,444 | $0.00 | - | |
| ||||||
| Stanley Frankel - Director | Open-market purchase | Common Stock | 2,700 | $4.97 | $13K | |
| Melinda Brown - Director | Open-market purchase | Common Stock | 1,400 | $4.89 | $7K | |
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Item 5.02, 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 1.01, 2.03, 9.01
DTIL insider trading FAQ
What is the latest insider trade for DTIL?
PRECISION BIOSCIENCES INC (DTIL) had 3 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for DTIL runs to 38 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DTIL stock?
3 insider purchases of DTIL were filed in the last 90 days, totaling $30K.
How many insiders are selling DTIL stock?
No insider sales of DTIL were filed in the last 90 days. 14 sales are on record for this company.
Where can I see DTIL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DTIL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Stanley Frankel view on EDGAR
- - Melinda Brown view on EDGAR
- - Geno J. Germano view on EDGAR
- - Melinda Brown view on EDGAR
- - Stanley Frankel view on EDGAR
- - Geno J. Germano view on EDGAR
- - Shari Lisa Pire view on EDGAR
- - Kevin Buehler view on EDGAR
- - J. Jefferson Smith view on EDGAR
- - Dario Scimeca view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where DTIL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DTIL with a 7-day demo
- DTIL on your watchlist
- Every DTIL Form 4 filing on record
- Up to 3 months of DTIL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.